Jan 21, 2026 04:00PM
Nov 12, 2025 12:16PM
Nov 12, 2025 08:02AM
Oct 16, 2025 06:03AM
Oct 15, 2025 07:07AM
Oct 15, 2025 03:42AM
Oct 15, 2025 03:42AM Citizens Downgrades Astria Therapeutics (ATXS) to Market Perform
Oct 14, 2025 04:34PM
Oct 14, 2025 06:55AM
Oct 9, 2025 06:43AM
Oct 3, 2025 06:42AM
Sep 18, 2025 06:57AM
Aug 13, 2025 04:05AM
Aug 12, 2025 05:46PM Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 8c
Aug 6, 2025 08:01AM
Jun 16, 2025 06:40AM
Jun 13, 2025 07:00AM
May 29, 2025 04:05AM
May 14, 2025 09:00AM
May 14, 2025 04:09AM
May 13, 2025 04:11PM Astria Therapeutics, Inc. (ATXS) Misses Q1 EPS by 13c
May 1, 2025 08:03AM
Apr 29, 2025 06:33AM
Apr 23, 2025 04:15AM
Mar 3, 2025 04:32AM
Feb 18, 2025 04:12AM
Jan 31, 2025 04:43AM
Jan 31, 2025 03:29AM JMP Securities Starts Astria Therapeutics (ATXS) at Market Outperform
Jan 24, 2025 06:42AM
Jan 13, 2025 08:03AM
Dec 10, 2024 08:08AM
Nov 20, 2024 07:39AM
Nov 13, 2024 04:11PM
Oct 16, 2024 08:05AM
Sep 30, 2024 08:01AM Astria Therapeutics (ATXS) Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
Sep 27, 2024 06:48AM
Sep 25, 2024 11:07AM
Aug 13, 2024 09:29AM
Aug 13, 2024 07:51AM
Aug 13, 2024 06:04AM
Aug 12, 2024 04:21PM
Aug 12, 2024 04:01PM Astria Therapeutics (ATXS) Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
Jul 29, 2024 05:29AM

408,209 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All